Jiang Qian - LianBio ADR China Mang
| LIANDelisted Stock | USD 2.18 0.05 2.24% |
Insider
Jiang Qian is China Mang of LianBio ADR
| Age | 56 |
| Phone | 609 486 2308 |
| Web | https://www.lianbio.com |
LianBio ADR Management Efficiency
The company has return on total asset (ROA) of (0.2167) % which means that it has lost $0.2167 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3242) %, meaning that it created substantial loss on money invested by shareholders. LianBio ADR's management efficiency ratios could be used to measure how well LianBio ADR manages its routine affairs as well as how well it operates its assets and liabilities.LianBio ADR currently holds 4.34 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. LianBio ADR has a current ratio of 15.49, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about LianBio ADR's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Alexander MS | Fennec Pharmaceuticals | N/A | |
| Christine MBA | Hookipa Pharma | 59 | |
| Eric MD | Acumen Pharmaceuticals | 69 | |
| MA MS | Inozyme Pharma | N/A | |
| Nancy Ruiz | Larimar Therapeutics | N/A | |
| Senthil Sundaram | Terns Pharmaceuticals | 46 | |
| Lieping MD | NextCure | 67 | |
| MHROD SHRMSCP | Assembly Biosciences | N/A | |
| David Hanley | Nuvation Bio | 54 | |
| Andreas Bergthaler | Hookipa Pharma | N/A | |
| Charles II | Day One Biopharmaceuticals | 47 | |
| Sumita JD | Instil Bio | 50 | |
| Mike Preigh | Day One Biopharmaceuticals | N/A | |
| BSc FRCPath | Achilles Therapeutics PLC | 59 | |
| Joern Aldag | Hookipa Pharma | 65 | |
| Mark Meier | Fennec Pharmaceuticals | N/A | |
| Janice Hitchcock | Acumen Pharmaceuticals | N/A | |
| Demetrios MD | Inozyme Pharma | N/A | |
| Kerry MD | Terns Pharmaceuticals | N/A | |
| MBA MBA | Inozyme Pharma | 65 | |
| Stefan Riley | Inozyme Pharma | N/A | |
Management Performance
| Return On Equity | -0.32 | |||
| Return On Asset | -0.22 |
LianBio ADR Leadership Team
Elected by the shareholders, the LianBio ADR's board of directors comprises two types of representatives: LianBio ADR inside directors who are chosen from within the company, and outside directors, selected externally and held independent of LianBio. The board's role is to monitor LianBio ADR's management team and ensure that shareholders' interests are well served. LianBio ADR's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, LianBio ADR's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jiang Qian, China Mang | ||
| Konstantin Poukalov, Founder Chairman | ||
| Ji Chen, Senior Counsel | ||
| Debra MD, Pres Officer | ||
| Levvy Eng, Senior Development | ||
| Adam Stone, Interim Director | ||
| Ehong Gu, VP CFO | ||
| Yizhe Wang, CEO Director | ||
| Yi MBA, CFO Treasurer | ||
| Michael MD, Chief Advisor | ||
| Brianne Jahn, Chief Officer |
LianBio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is LianBio ADR a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.32 | |||
| Return On Asset | -0.22 | |||
| Current Valuation | (182.65 M) | |||
| Shares Outstanding | 108.06 M | |||
| Shares Owned By Insiders | 5.90 % | |||
| Shares Owned By Institutions | 78.99 % | |||
| Number Of Shares Shorted | 378.13 K | |||
| Price To Book | 0.15 X | |||
| EBITDA | (105.26 M) | |||
| Net Income | (87.98 M) |
Pair Trading with LianBio ADR
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if LianBio ADR position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in LianBio ADR will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to LianBio ADR could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace LianBio ADR when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back LianBio ADR - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling LianBio ADR to buy it.
The correlation of LianBio ADR is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as LianBio ADR moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if LianBio ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for LianBio ADR can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Consideration for investing in LianBio Stock
If you are still planning to invest in LianBio ADR check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the LianBio ADR's history and understand the potential risks before investing.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |